Dr. Siegall co-founded Seattle Genetics, Inc. in 1997. He has been its president since June 2000 and CEO since November 2002. Additionally, Dr. Siegall is Chairman of the Board. Seattle Genetics has brought numerous developments to the company since he was elected president and CEO. Under his direction, the company has created a broad pipeline of antibody-drug conjugate (ADCs) for the treatment of cancer. Among the ADCs s the ADCETRIS that was approved by the U.S. FDA in 2011. Clay Siegall has over 15 years of experience in cancer research and therapeutic drug development.
He has worked at major biotechnology companies including Bristol-Myers Squibb Pharmaceutical Research Institute, Alder Biopharmaceuticals, Ultragenyx Pharmaceutical Inc, Washington Biotechnology and Biomedical Association among others. Clay Siegall also joined Mirna Therapeutics, a biotechnology-based company in January 2013. He was appointed to join the Board of Directors as an outside director.
Seattle Genetics is a biotechnology corporation that centers on the development and commercialization of therapies for the treatment of cancer and autoimmune diseases. Incorporated on July 15, 1997, the company’s product ADCETRIS (brentuximab vedotin), is an antibody-drug conjugate (ADC) which comprises of an anti-CD30 monoclonal antibody held by a protease-cleavable linker to monomethyl auristatin E (MMAE).
Apart from ADCETRIS (brentuximab vedotin), the Company’s pipeline in various stages of clinical trials consists of SGN-CD19A, SGN-CD33A, SGN-CD70A, ASG-22ME, SGN-LIV1A, and ASG-15ME, and SEA-CD40, an ADC based on its sugar-engineered antibody SEA technology.
This product uses a linker system formulated to stabilize in the bloodstream to release cell-killing agent, MMAE directly into CD30-positive cells. Regulatory authorities in over 60 nations have approved marketing authorization of brentuximab vedotin in relapsed systemic anaplastic large cell lymphoma (sALCL) and relapsed Hodgkin lymphoma.
The product has also been approved for intravenous injection for three indications including standard approval for the treatment of relapsed classical Hodgkin lymphoma; standard approval for the treatment of patients suffering from classical HL when auto-hematopoietic stem cell transplantation or multi-agent chemotherapy regimens fails and for the treatment of patients suffering from sALCL when one prior multi-agent chemotherapy regimen fails.
Seattle Genetics in collaboration with Takeda Pharmaceutical Company are responsible for the development of ADCETRIS (brentuximab vedotin). The two biotechnology companies finance joint worldwide development expenses on a 50:50 basis, apart from in Japan where Takeda takes care of the development costs. The collaboration gives Seattle Genetics sole commercialization rights in the United States and Canada while Takeda Pharmaceutical Company has commercialization rights in the rest of the globe.